Streetbeat News

Stock Prices

BTCUSD

ETHUSD

FTTUSD

LUNCUSD

Cryptocurrency prices fluctuated with Bitcoin and Ethereum remaining above key levels of $37,000 and $2,000 respectively. FTX Token was the top gainer, while Terra Classic was the biggest loser in the last 24 hours. The global crypto market cap declined by 1.4% to $1.4 trillion. Other notable gainers include Celestia, Toncoin, Oasis Network, and Uniswap, while The Graph, Blur, Gala, and Theta Network were among the losers.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 2:38 pm

LEXX

Lexaria Bioscience reported interim results from a human pilot study evaluating its DehydraTECH technology for oral delivery of semaglutide, a drug found in Rybelsus. The study showed that DehydraTECH-powered semaglutide sustained lower blood glucose levels, including nearly 10 times lower after 24 hours, and reduced blood-glucose spikes after eating. This marks the first successful DehydraTECH test with a large molecule drug.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:36 pm

ANIK

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced the first successful surgeries using its Integrity Implant System for rotator cuff repairs, marking its entry into the $150 million+ U.S. rotator cuff augmentation market. The FDA-cleared system includes a hyaluronic acid-based scaffold and is part of Anika's expanding regenerative product portfolio. The limited market release of Integrity is ahead of schedule, with a full market release expected in Q1 2024. The system is designed to promote healing and has shown superior results compared to the leading collagen implant in an animal study. Anika's comprehensive rotator cuff solution portfolio positions the company as a key player in orthopedic regenerative solutions and sports medicine.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:36 pm

DRCT

Shares of Direct Digital Holdings were halted due to a circuit breaker after falling 15.3%. This indicates a significant drop in the company's stock price, triggering a temporary pause in trading to prevent further immediate decline.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:35 pm

XXII

22nd Century Group, Inc. (NASDAQ:XXII) has agreed to sell its GVB Biopharma hemp/cannabis operations to Specialty Acquisition Corporation for $2.25 million. The deal includes a $1 million payment at closing and a $1.25 million secured promissory note. The sale aims to reduce cash and operating demands, with 22nd Century expecting to lower operating expenses beyond the $15 million in annual cost savings already announced. The company will retain rights to insurance proceeds from a fire at its Grass Valley facility, with damages sought at approximately $9 million. The sale is set to close in early December 2023, pending customary conditions and financing for the buyer. 22nd Century is also exploring strategic alternatives for its tobacco assets, including its FDA-approved VLN reduced nicotine content products.

Portfolio Pulse from Nina Zdinjak

November 28, 2023 | 2:35 pm

MNY

Shares of MoneyHero (MNY) were halted due to a circuit breaker after surging 22.4% to the upside. The halt is a mechanism to prevent excessive volatility in the stock market.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:34 pm

SWTX

HC Wainwright & Co. analyst Robert Burns has reaffirmed a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) and increased the price target from $52 to $64.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:33 pm

INVO

INVO Bioscience, Inc. (NASDAQ:INVO) has regained compliance with Nasdaq's minimum stockholders' equity requirement after previously failing to meet the standard. This was achieved through a share exchange agreement with Cytovia Therapeutics Holdings, Inc., which acquired 1,200,000 shares of INVO's Series B Preferred Stock in exchange for shares of NAYA Biosciences Inc. INVO's improved financial position, including a significant reduction in net loss and reduced operating costs, contributed to meeting Nasdaq's listing criteria. Additionally, INVO is in the process of merging with NAYA Biosciences in an all-stock transaction, pending certain conditions.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:32 pm

BMY

RNA

Avidity Biosciences' stock is trading higher following the announcement of an expanded cardiovascular collaboration with Bristol Myers Squibb, valued at $2.3 billion. Avidity will receive an upfront payment of $100 million.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:31 pm

EIS

A ceasefire between Israel and Hamas is holding, with ongoing hostage swaps. Israel has released 150 Palestinian detainees, while Hamas has freed 50 Israeli women and children. Negotiations are intensifying to extend the truce and secure the release of all remaining hostages. Diplomatic efforts include Mossad Chief David Barnea's discussions in Doha. Bernie Sanders criticized the US's unconditional support for Israel, and the WHO warned of a health crisis in Gaza. The shekel strengthened, and domestic stocks rose, with the iShares MSCI Israel ETF (EIS) reaching its highest level since early October.

Portfolio Pulse from Piero Cingari

November 28, 2023 | 2:26 pm